• Phase III Trial for Nirogacestat : “A new company named SpringWorks Therapeutics has been formed as a spinoff of Pfizer to focus on investigational therapies that hold significant promise for underserved populations…”
  • Phase I Trial for Tegavivint : “At our 11th DTRF Annual Patient Meeting in Philadelphia, we were pleased to have Beta Cat Pharmaceuticals’ Jon Northrup, Chief Executive Officer, and Casey Cunningham, Chief Medical Officer, present an outline of the planned clinical trial of Tegavivint, a new drug that directly interferes with beta-catenin stabilization…”

Read More at the Desmoid Tumor Research Foundation website